In breast cancer, atezolizumab, a PD-L1 antibody with ADCC activity against PD-L1 positive TNBC was shown to be effective (16), while malignant pleural mesothelioma achieved better treatment outcomes when treated using a combination of anti CTLA-4 and PD-1 antibodies (17). This evidence concerns the gene PDCD1 and malignant pleural mesothelioma.